Correction: The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D-An exploratory RCT

更正：一项探索性随机对照试验研究了单独使用罗伊氏乳杆菌ATCC PTA 6475以及与罗伊氏乳杆菌DSM 17938联合使用6周干预对腹泻型肠易激综合征（IBS-D）患者肠道屏障功能、免疫标志物和症状的影响。